We are updating our site to better serve you
COLCRYS is covered at the lowest branded co-pay tier with no restrictions for more than 80% of insured patients nationwide. This includes patients with commercial, Medicare Part D, or Medicaid prescription benefits.*
Most privately insured patients pay only $15 per prescription† with a COLCRYS Co-pay Coupon. All patients have access to a FREE 7-tablet voucher.‡
Learn about all the money-saving options available for COLCRYS patients, including:
- Co-pay Assistance Program
- FREE 7-tablet voucher
- Patient Assistance Program (PAP)
- Reimbursement Hotline to help you understand your prescription coverage
Download Full Prescribing Information | Download Patient Prescribing Information
*Patients with health insurance in the Fingertip Formulary database. Fingertip Formulary data as of January 26, 2012. This includes patients with commercial, Medicare Part D, or Medicaid prescription benefits.
†Maximum savings of $75 per prescription. Void or not available in certain states. Patients not eligible if prescriptions are paid in full or part by any state or federally funded programs, including but not limited to Medicare or Medicaid, Medigap, VA, DOD, or TRICARE, and where prohibited by law.
‡Restrictions apply.
Indication: COLCRYS (colchicine, USP) 0.6-mg tablets are indicated in adults for the prophylaxis of gout flares and treatment of acute gout flares when taken at the first sign of a flare.
Limitation of use: COLCRYS is not an analgesic medication and should not be used to treat pain from other causes.
Contraindications: Patients with renal or hepatic impairment should not be given COLCRYS in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors, except fosamprenavir). In these patients, life-threatening and fatal colchicine toxicity has been reported with colchicine taken in therapeutic doses.
Important Safety Information
COLCRYS is contraindicated in patients with renal or hepatic impairment who are concurrently prescribed P-gp inhibitors or strong inhibitors of CYP3A4 as life-threatening or fatal toxicity has been reported. Dose adjustments of COLCRYS may be required when co-administered with P-gp or CYP3A4 inhibitors. Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine. Keep COLCRYS out of the reach of children. Myelosuppression, thrombocytopenia, and leukopenia have been reported in patients taking colchicine at therapeutic doses. Rhabdomyolysis has been occasionally observed, especially when colchicine is prescribed in combination with other drugs known to cause this effect. Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses. Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk. Monitoring is recommended for patients with a history of blood dyscrasias or rhabdomyolysis. The most common adverse events in clinical trials were diarrhea and pharyngolaryngeal pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
You may also report negative side effects to the manufacturer of COLCRYS by calling 1-888-351-3786.
Please see full Prescribing Information.